Madeleine M Verhovsek

List of Publications by Year
in descending order

44 papers	885 citations	686830 13 h-index	476904 29 g-index
47 all docs	47 docs citations	47 times ranked	1150 citing authors

#	Article	IF	Citations
1	Ketamine administration for acute painful sickle cell crisis: AÂrandomized controlled trial. Academic Emergency Medicine, 2022, 29, 150-158.	0.8	19
2	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. New England Journal of Medicine, 2022, 386, 1432-1442.	13.9	42
3	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	1.1	17
4	Stuttering Priapism in a Patient with Sickle Cell Trait Treated with Automated Red Cell Exchange Transfusion. Blood Advances, 2021, 5, 5020-5022.	2.5	1
5	Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers. Blood, 2021, 138, 4173-4173.	0.6	1
6	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	0.6	1
7	A novel means of identifying hemoglobin Tacoma utilizing capillary electrophoresis with a hemoglobin A1c software platform. Cogent Medicine, 2021, 8, .	0.7	1
8	Combined preoperative plasma exchange and red blood cell exchange transfusion in a renal transplant patient with protein S deficiency and hemoglobin SC disease. Transfusion and Apheresis Science, 2021, , 103345.	0.5	0
9	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	2.0	8
10	Microcytosis in patients with haemoglobin C trait: is Î±â€thalassaemia trait to blame?. British Journal of Haematology, 2020, 191, e129-e131.	1.2	0
11	Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to riskâ€stratify patients for alloimmunisation risk. Transfusion Medicine, 2020, 30, 263-274.	0.5	3
12	Novel High Oxygen Affinity Hemoglobin Variant in a Patient with Polycythemia: Hb Kennisis [Î²85(F1)Pheâ†'Leu (TTT>TTG); HBB: c.258T>G]. Hemoglobin, 2020, 44, 10-12.	0.4	2
13	Genotypeâ€phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	2.0	47
14	Pharmacy hydroxyurea education materials for patients with sickle cell disease: An environmental scan and assessment of accuracy. Pediatric Blood and Cancer, 2020, 67, e28179.	0.8	1
15	Emergency Department Quality of Care for Sickle Cell Disease in Ontario, Canada: A Population-Based Matched Cohort Study. Blood, 2020, 136, 38-39.	0.6	2
16	How we diagnose and manage altered oxygen affinity hemoglobin variants. American Journal of Hematology, 2019, 94, 597-603.	2.0	38
17	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Advances, 2019, 3, 3867-3897.	2.5	87
18	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	1.7	46

#	Article	IF	Citations
19	The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?. , 2019, 16, .		2
20	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	0.6	0
21	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	0.6	0
22	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	0.6	1
23	Treating iron deficiency. Cmaj, 2017, 189, E409-E409.	0.9	5
24	Hb Grifton [Î±87(F8)Hisâ†'Pro;HBA1: C.263Aâ€‰>â€‰C (orHBA2)] Causes Abnormal Pulse Oximetry Measurements. Hemoglobin, 2016, 40, 257-259.	0.4	1
25	A 19-year-old woman with sickle cell disease and pain. Cmaj, 2016, 188, 745-746.	0.9	1
26	Pilot Study of Online Learning Modules for Hemoglobinopathy Education in Canadian Hematology Training Programs. Blood, 2016, 128, 314-314.	0.6	1
27	Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report. African Health Sciences, 2015, 14, 1069.	0.3	1
28	Red Cell Antigen Genotyping Compared to Standard Serological Phenotyping in Sickle Cell Disease Patients in Canada: Potential for Reducing Alloimmunization. Blood, 2015, 126, 3404-3404.	0.6	0
29	Haptoglobin testing in hemolysis: Measurement and interpretation. American Journal of Hematology, 2014, 89, 443-447.	2.0	107
30	Hemoglobinopathy Education in Canadian Hematology Training Programs: How Much Are Residents Learning?. Blood, 2014, 124, 2168-2168.	0.6	0
31	Transition of Care Under One Roof at the Mcmaster Hemoglobinopathy Clinic. Blood, 2014, 124, 4851-4851.	0.6	1
32	Radiologyâ€"pathology conference: neutrophilic fasciitis and panniculitis of the feet (Sweet's) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	0.8	1
33	Pulse oximetry screening for critical congenital heart defects. Lancet, The, 2012, 380, 1305-1306.	6.3	0
34	Severe fetal and neonatal hemolytic anemia due to a 198â€‰kb deletion removing the complete Î²â€globin gene cluster. Pediatric Blood and Cancer, 2012, 59, 941-944.	0.8	11
35	Is HbA2 level a reliable diagnostic measurement for Î²-thalassemia trait in people with iron deficiency?. American Journal of Hematology, 2012, 87, 114-116.	2.0	26
36	Hb A₂Hong Kong â€" A Novel Î´-Globin Variant in a Chinese Family Masks the Diagnosis of Î²-Thalassemia Trait. Hemoglobin, 2011, 35, 162-165.	0.4	12

#	Article	IF	Citations
37	Unexpectedly low pulse oximetry measurements associated with variant hemoglobins: A systematic review. American Journal of Hematology, 2010, 85, 882-885.	2.0	72
38	Variability In Hb A2 levels among Individuals with Beta-Thalassemia Trait: Is Iron Deficiency Associated with Abnormally Low Hb A2?. Blood, 2010, 116, 4281-4281.	0.6	1
39	Severe Fetal and Neonatal Anemia Due to Heterozygosity for a 198 Kb Deletion Removing the Entire Î²-Globin Gene Cluster. Blood, 2010, 116, 5171-5171.	0.6	0
40	Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial. Journal of Thrombosis and Thrombolysis, 2009, 28, 266-268.	1.0	3
41	Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review. BMC Geriatrics, 2008, 8, 13.	1.1	41
42	Laboratory testing for fibrinogen abnormalities. American Journal of Hematology, 2008, 83, 928-931.	2.0	39
43	Systematic Review: <scp>d</scp>-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2008, 149, 481.	2.0	234
44	Existing Warfarin Therapy in Long-Term Care Facilities Maybe Inadequate.. Blood, 2005, 106, 4160-4160.	0.6	0